This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
by Zacks Equity Research
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
by Zacks Equity Research
Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.
Top Ranked Momentum Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $89.89, marking a +1.02% move from the previous day.
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $96.47, marking a -0.94% move from the previous day.
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Seattle Genetics Begins Phase III Study on Tucatinib Combo
by Zacks Equity Research
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
by Zacks Equity Research
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Seattle Genetics Up More Than 20% in 3 Months: Here's Why
by Zacks Equity Research
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Exact Sciences Corporation Enters Oversold Territory
by Zacks Equity Research
Exact Sciences Corporation has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health